sulfasalazine has been researched along with Diarrhea in 77 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " At the time of a planned interim toxicity analysis, more patients with grade ≥3 diarrhea received sulfasalazine than received placebo (29% vs 11%, P=." | 9.22 | N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. ( Bearden, JD; Iott, MJ; Liem, B; Liu, H; Loprinzi, CL; Martenson, JA; Miller, RC; Mowat, RB; Petereit, DG; Sapiente, R; Seeger, GR; Sloan, JA, 2016) |
| " The present study examined intestinal anti-inflammatory activity of coumarin and its derivative, the 4-hydroxycoumarin on experimental ulcerative colitis in rats." | 7.74 | Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis. ( Cestari, SH; Di Stasi, LC; Luchini, AC; Pellizzon, CH; Rodrigues-Orsi, P; Seito, LN; Witaicenis, A, 2008) |
| "Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption." | 5.40 | Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. ( Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 5.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| " At the time of a planned interim toxicity analysis, more patients with grade ≥3 diarrhea received sulfasalazine than received placebo (29% vs 11%, P=." | 5.22 | N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. ( Bearden, JD; Iott, MJ; Liem, B; Liu, H; Loprinzi, CL; Martenson, JA; Miller, RC; Mowat, RB; Petereit, DG; Sapiente, R; Seeger, GR; Sloan, JA, 2016) |
| "We report large-volume secretory diarrhea and intestinal pseudo-obstruction in a man whom ultimately proved to have Crohn's disease that responded to sulfasalazine and steroids with resolution of all his symptoms." | 4.79 | Massive secretory diarrhea and pseudo-obstruction as the initial presentation of Crohn's disease. ( Carethers, JM; McDonnell, WM; Owyang, C; Scheiman, JM, 1996) |
| "Although oral mesalamine is the first-choice drug for treating mild-to-moderate ulcerative colitis (UC), some patients show symptoms of intolerance, including exacerbation of diarrhea and abdominal pain." | 4.02 | Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. ( Fujiwara, A; Higashi, R; Hiraoka, S; Inokuchi, T; Kato, J; Matsueda, K; Miyaike, J; Moritou, Y; Okada, H; Suzuki, S; Takagi, S; Takahara, M; Toyokawa, T, 2021) |
| "Sulfasalazine and FTY720 treatment did not prevent body weight loss or reduce clinical scores of diarrhea or intestinal gross pathology, when compared with vehicle treatment." | 3.77 | Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model. ( Benson, EL; Heuvelman, DM; Masferrer, JL; Radi, ZA, 2011) |
| " The present study examined intestinal anti-inflammatory activity of coumarin and its derivative, the 4-hydroxycoumarin on experimental ulcerative colitis in rats." | 3.74 | Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis. ( Cestari, SH; Di Stasi, LC; Luchini, AC; Pellizzon, CH; Rodrigues-Orsi, P; Seito, LN; Witaicenis, A, 2008) |
| " Clinically, pro-drugs such as olsalazine have been associated with dose-dependent diarrhea, which was likely secondary to ileal secretion induced by the azo linkages, in 17% of patients." | 3.73 | Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. ( Chang, EB; Hanauer, SB; Kles, KA; Musch, MW; Turner, JR; Vavricka, SR, 2005) |
| "1 yr) had been treated with antidiarrheals (6), sulfasalazine (3), discontinuation of NSAIDS (3), reversal of jejunoilial bypass (1), or nothing (4)." | 3.69 | Collagenous colitis: histopathology and clinical course. ( Appelman, HD; Barnett, JL; Goff, JS; Pelke, T, 1997) |
| "A total of 162 patients with ulcerative colitis in remission." | 2.68 | Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. ( Hentschel, E; Judmaier, G; Kayasseh, L; Kratochvil, P; Kruis, W; Scheurlen, C; Stolte, M; Theuer, D, 1995) |
| "In patients suffering from ulcerative colitis grade II and III the effect of Boswellia serrata gum resin preparation (350 mg thrice daily for 6 weeks) on stool properties, histolopathology and scan microscopy of rectal biopsies, blood parameters including Hb, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils was studied." | 2.68 | Effects of Boswellia serrata gum resin in patients with ulcerative colitis. ( Ammon, HP; Gupta, I; Lüdtke, R; Malhotra, P; Parihar, A; Safayhi, H; Singh, GB, 1997) |
| "Microscopic colitis is a recently recognized cause of diarrhoea, predominantly affecting older women, but its response to treatment is poorly documented." | 2.67 | Response to treatment of microscopic colitis. ( Fasoli, R; Jewell, DP, 1994) |
| "Radiation enteritis is a severe problem in patients receiving irradiation of the abdomen or pelvis in the course of cancer treatment." | 2.44 | Medical prevention and treatment of acute and chronic radiation induced enteritis--is there any proven therapy? a short review. ( Böcker, U; Singer, MV; Wenz, F; Zimmerer, T, 2008) |
| "Lymphocytic colitis is a rare clinicopathologic syndrome, characterized by chronic watery diarrhea, diffuse inflammatory changes in the colonic mucous in spite of normal findings on colonoscopy and marked intraepithelial lymphocytic infiltration on biopsy." | 2.41 | [Lymphocytic colitis: hypopotassemia as a complication and an association with toxic multinodular goiter]. ( Arenas Gracia, M; Calduch Broseta, JV; Martínez López, V; Mata Medina, B; Segarra Soria, MM; Serrano Corredor, MS, 2000) |
| "Pseudomembranous colitis is caused by antibiotics facilitating an overgrowth of Clostridium difficile." | 2.41 | [Drug-induced enterocolitis. Important differential diagnosis in the investigation of diarrhea and intestinal hemorrhage]. ( Tysk, C, 2000) |
| "A case of Basedow's disease, that developed after successful treatment of ulcerative colitis with a total colectomy, is presented, along with a review of the Japanese literature on the coexistence of hyperthyroidism and ulcerative colitis." | 2.41 | Basedow's disease and chronic ulcerative colitis: a case report and review of the Japanese literature. ( Hada, T; Iijima, H; Moriwaki, Y; Nishimura, M; Takahashi, S; Yamamoto, T, 2001) |
| "Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption." | 1.40 | Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. ( Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014) |
| " Recent experience indicates that the most effective dosage of nystatin for dogs and cats is 50." | 1.35 | [A cat with diarrhoea associated with the massive presence of Cyniclomyces guttulatus in the faeces]. ( Houwers, DJ; Peters, S, 2009) |
| "The diagnosis of a relapsing polyradiculoneuritis associated with Crohn's disease was retained." | 1.34 | [Crohn's disease presenting with recurrent acute polyradiculoneuropathy]. ( El Moutawakil, B; Gam, I; Rafai, MA; Rhimou, A; Slassi, I; Tahiri, JM, 2007) |
| "Co-occurence of systemic sclerosis and collagenous colitis is particularly rare." | 1.34 | Collagenous colitis in a patient with systemic sclerosis: a rare entity. ( Coban, S; Ekiz, F; Ensari, A; Gören, D; Ormeci, N; Savas, B, 2007) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 1.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "One patient was a 14-year-old male with acute myelogenous leukemia who received SCT from a related HLA-identical donor." | 1.32 | Experience with the use of salazosulfapyridine for intractable diarrhea after hematopoietic stem cell transplantation. ( Ando, A; Isokawa, S; Miyata, H; Moriguchi, N, 2004) |
| "Colitis was induced by feeding a diet containing 0." | 1.31 | Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. ( Andoh, A; Araki, Y; Bamba, T; Hibi, T; Iwanaga, T; Kanauchi, O; Mitsuyama, K; Nakamura, T; Suzuki, A, 2001) |
| "Diarrhea is a non-specific symptom which may be associated with Addison's disease and several causes had been demonstrated in the aetiology." | 1.30 | Collagenous colitis in a patient with Addison's disease: a case report. ( Bayram, F; Keleştimur, F; Kirgin, A; Ozbakir, O; Patiroglu, T; Unlühizarci, K; Yücesoy, M, 1998) |
| "In patients with Crohn's disease not taking corticosteroids, IgM lipocortin-I antibody levels were directly related to disease activity scored clinically." | 1.29 | Antibodies to human recombinant lipocortin-I in inflammatory bowel disease. ( Rampton, DS; Smith, SF; Stevens, TR, 1993) |
| "Prednisolone was most effective with a response rate of 82%, but the required dose was often high and the effect was not sustained after withdrawal." | 1.29 | Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. ( Abrahamsson, H; Bohr, J; Eriksson, S; Järnerot, G; Tysk, C, 1996) |
| "Sulfasalazine is an important therapeutic agent in the management of chronic inflammatory bowel disease (CIBD)." | 1.28 | Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. ( Tolia, V, 1992) |
| "Microscopic colitis has been observed to precede collagenous colitis in some patients." | 1.28 | Collagenous colitis as a cause of chronic diarrhea. ( Bott, SJ, 1990) |
| "These are all beneficial in treating gastroduodenal ulceration." | 1.27 | The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical gastrointestinal effects. ( Isselbacher, KJ, 1987) |
| "Etiology and pathogenesis of Crohn's disease, the incidence of which seems to be increasing lately, are still unknown." | 1.26 | [Clinical features of inflammatory bowel disease (author's transl)]. ( Classen, M; Leuschner, U; Strohm, WD, 1982) |
| "Microscopic colitis is responsible for a proportion of cases of intractable diarrhoea of obscure origin and rectal and colonic biopsies sould be undertaken in such cases." | 1.26 | Microscopic colitis-a cause of chronic watery diarrhoea. ( Ball, JA; Dawson, AM; Kingham, JG; Levison, DA, 1982) |
| "Recurrences were more frequent in patients under than over 31 years of age at their first operation." | 1.26 | [Crohn's disease: course and prognosis in 169 patients (author's transl)]. ( Classen, M; Mörl, M; Zöberlein, HG, 1978) |
| "In acute exacerbations of ulcerative colitis, the potential difference was reversed, the luminal side being positive." | 1.25 | Electrical potentials of the sigmoid colon and rectum in irritable bowel syndrome and ulcerative colitis. ( Edmonds, CJ, 1970) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (46.75) | 18.7374 |
| 1990's | 20 (25.97) | 18.2507 |
| 2000's | 14 (18.18) | 29.6817 |
| 2010's | 6 (7.79) | 24.3611 |
| 2020's | 1 (1.30) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraoka, S | 1 |
| Fujiwara, A | 1 |
| Toyokawa, T | 1 |
| Higashi, R | 1 |
| Moritou, Y | 1 |
| Takagi, S | 1 |
| Matsueda, K | 1 |
| Suzuki, S | 1 |
| Miyaike, J | 1 |
| Inokuchi, T | 1 |
| Takahara, M | 1 |
| Kato, J | 1 |
| Okada, H | 1 |
| Hoversten, P | 1 |
| Beachey, J | 1 |
| Pham, M | 1 |
| Bhagra, A | 1 |
| Ding, H | 1 |
| Liu, XC | 1 |
| Mei, Q | 1 |
| Xu, JM | 1 |
| Hu, XY | 1 |
| Hu, J | 1 |
| Miller, RC | 1 |
| Petereit, DG | 1 |
| Sloan, JA | 1 |
| Liu, H | 1 |
| Martenson, JA | 1 |
| Bearden, JD | 1 |
| Sapiente, R | 1 |
| Seeger, GR | 1 |
| Mowat, RB | 1 |
| Liem, B | 1 |
| Iott, MJ | 1 |
| Loprinzi, CL | 1 |
| Luchini, AC | 1 |
| Rodrigues-Orsi, P | 1 |
| Cestari, SH | 1 |
| Seito, LN | 1 |
| Witaicenis, A | 1 |
| Pellizzon, CH | 1 |
| Di Stasi, LC | 1 |
| Peters, S | 1 |
| Houwers, DJ | 1 |
| Nizam, S | 1 |
| Johnstone, A | 1 |
| Ridpath, J | 1 |
| Davies, G | 1 |
| Gough, A | 1 |
| Jiang, GL | 1 |
| Im, WB | 1 |
| Donde, Y | 1 |
| Wheeler, LA | 1 |
| Radi, ZA | 1 |
| Heuvelman, DM | 1 |
| Masferrer, JL | 1 |
| Benson, EL | 1 |
| Mukherjee, S | 1 |
| Moriguchi, N | 1 |
| Isokawa, S | 1 |
| Ando, A | 1 |
| Miyata, H | 1 |
| Kles, KA | 1 |
| Vavricka, SR | 1 |
| Turner, JR | 1 |
| Musch, MW | 1 |
| Hanauer, SB | 1 |
| Chang, EB | 1 |
| El Moutawakil, B | 1 |
| Rafai, MA | 1 |
| Gam, I | 1 |
| Tahiri, JM | 1 |
| Rhimou, A | 1 |
| Slassi, I | 1 |
| Ekiz, F | 1 |
| Coban, S | 1 |
| Savas, B | 1 |
| Gören, D | 1 |
| Ensari, A | 1 |
| Ormeci, N | 1 |
| Zimmerer, T | 1 |
| Böcker, U | 1 |
| Wenz, F | 1 |
| Singer, MV | 1 |
| Buisseret, P | 1 |
| Hansen, W | 1 |
| Leuschner, U | 1 |
| Strohm, WD | 1 |
| Classen, M | 2 |
| Chadwick, VS | 1 |
| Nielsen, OH | 1 |
| Kingham, JG | 1 |
| Levison, DA | 1 |
| Ball, JA | 1 |
| Dawson, AM | 1 |
| Larizza, D | 1 |
| Boni, R | 1 |
| Strum, WB | 1 |
| Greenfield, C | 1 |
| Aguilar Ramirez, JR | 1 |
| Pounder, RE | 1 |
| Williams, T | 1 |
| Danvers, M | 1 |
| Marper, SR | 1 |
| Noone, P | 1 |
| Hutchinson, D | 1 |
| Wyld, PJ | 1 |
| Iwatsuki, K | 1 |
| Tsugiki, M | 1 |
| Tagami, H | 1 |
| Yamada, M | 1 |
| Ewe, K | 1 |
| Kruis, W | 1 |
| Judmaier, G | 1 |
| Kayasseh, L | 1 |
| Stolte, M | 1 |
| Theuer, D | 1 |
| Scheurlen, C | 1 |
| Hentschel, E | 1 |
| Kratochvil, P | 1 |
| Zins, BJ | 1 |
| Sandborn, WJ | 1 |
| Tremaine, WJ | 1 |
| Nilsson, A | 1 |
| Danielsson, A | 1 |
| Löfberg, R | 1 |
| Benno, P | 1 |
| Bergman, L | 1 |
| Fausa, O | 1 |
| Florholmen, J | 1 |
| Karvonen, AL | 1 |
| Kildebo, S | 1 |
| Kollberg, B | 1 |
| Brady, SK | 1 |
| McKee, DD | 1 |
| Fasoli, R | 1 |
| Jewell, DP | 1 |
| De Waele, S | 1 |
| Janssens, P | 1 |
| Hoang, P | 1 |
| Laka, A | 1 |
| Lagneaux, G | 1 |
| Lambert, M | 1 |
| Stevens, TR | 1 |
| Smith, SF | 1 |
| Rampton, DS | 1 |
| Seewald, S | 1 |
| Schmidt, C | 1 |
| Klassen, PM | 1 |
| Vogel, J | 1 |
| Vetter, H | 1 |
| Carethers, JM | 1 |
| McDonnell, WM | 1 |
| Owyang, C | 1 |
| Scheiman, JM | 1 |
| Goff, JS | 1 |
| Barnett, JL | 1 |
| Pelke, T | 1 |
| Appelman, HD | 1 |
| Bohr, J | 1 |
| Tysk, C | 2 |
| Eriksson, S | 1 |
| Abrahamsson, H | 1 |
| Järnerot, G | 2 |
| Gupta, I | 1 |
| Parihar, A | 1 |
| Malhotra, P | 1 |
| Singh, GB | 1 |
| Lüdtke, R | 1 |
| Safayhi, H | 1 |
| Ammon, HP | 1 |
| Otero, S | 1 |
| Larrauri, J | 1 |
| Herrera, JM | 1 |
| Pizarro, A | 1 |
| García, E | 1 |
| Guil, A | 1 |
| Crivell, C | 1 |
| Cisneros, JM | 1 |
| Huang, JL | 1 |
| Chen, LC | 1 |
| Unlühizarci, K | 1 |
| Bayram, F | 1 |
| Ozbakir, O | 1 |
| Kirgin, A | 1 |
| Patiroglu, T | 1 |
| Yücesoy, M | 1 |
| Keleştimur, F | 1 |
| Arenas Gracia, M | 1 |
| Mata Medina, B | 1 |
| Serrano Corredor, MS | 1 |
| Calduch Broseta, JV | 1 |
| Martínez López, V | 1 |
| Segarra Soria, MM | 1 |
| Kiliç, D | 1 |
| Egehan, I | 1 |
| Ozenirler, S | 1 |
| Dursun, A | 1 |
| Nishimura, M | 1 |
| Yamamoto, T | 1 |
| Iijima, H | 1 |
| Moriwaki, Y | 1 |
| Takahashi, S | 1 |
| Hada, T | 1 |
| Kanauchi, O | 1 |
| Iwanaga, T | 1 |
| Andoh, A | 1 |
| Araki, Y | 1 |
| Nakamura, T | 1 |
| Mitsuyama, K | 1 |
| Suzuki, A | 1 |
| Hibi, T | 1 |
| Bamba, T | 1 |
| Iofel, E | 1 |
| Chawla, A | 1 |
| Daum, F | 1 |
| Markowitz, J | 1 |
| Kaplinsky, N | 1 |
| Frankl, O | 1 |
| Bennett, A | 1 |
| Bell, DR | 1 |
| Werlin, SL | 1 |
| Grand, RJ | 1 |
| Schroeder, W | 1 |
| Schwarzer, J | 1 |
| Mörl, M | 1 |
| Zöberlein, HG | 1 |
| van Hees, PA | 1 |
| Tuinte, JH | 1 |
| van Rossum, JM | 1 |
| van Tongeren, JH | 2 |
| Isaza, R | 1 |
| Baker, B | 1 |
| Dunker, F | 1 |
| Tolia, V | 1 |
| Butt, JH | 1 |
| Rijk, MC | 1 |
| van Schaik, A | 1 |
| Bott, SJ | 1 |
| Donowitz, M | 1 |
| Woodhouse, KW | 1 |
| Sandberg-Gertzén, H | 1 |
| Kraaz, W | 1 |
| Lee, DK | 1 |
| Cooper, BT | 1 |
| Barbezat, GO | 1 |
| Wiener, MD | 1 |
| Isselbacher, KJ | 1 |
| Bukhave, K | 1 |
| Lauritsen, K | 1 |
| Laursen, LS | 1 |
| Rask-Madsen, J | 1 |
| Fairburn, RA | 1 |
| Arvanitakis, C | 1 |
| Malek, G | 1 |
| Uehling, D | 1 |
| Morrissey, JF | 1 |
| Tumen, HJ | 1 |
| Kater, F | 1 |
| Wackers, FJ | 1 |
| Tytgat, GN | 1 |
| Vreeken, J | 1 |
| Gall, DG | 1 |
| Hamilton, JR | 1 |
| Niaudet, P | 1 |
| Schmitz, J | 1 |
| Jarriau, P | 1 |
| Schweisguth, O | 1 |
| Rey, J | 1 |
| Edmonds, CJ | 1 |
| Rauch, K | 1 |
| Weiland, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III, Randomized, Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy[NCT01198145] | Phase 3 | 87 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of patients reporting the use of anti-diarrheal medications divided by the number of patients evaluated for this endpoint. (NCT01198145)
Timeframe: Up to 24 months post radiotherapy
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I: Sulfasalazine | 48.7 |
| Arm II: Placebo | 28.6 |
"Questions that were used in this analysis:~2. Have you had a problem causing you to get up at night to have a bowel movement? 3. Have you had a problem causing you to lose control of your bowel movements? 4. Have you had a problem causing you to have a bowel movement within 30 minutes of a prior bowel movement? 5. Have you had to wear protective clothing or a pad in case you lost control of a bowel movement? 6. Have you had a problem causing you to be unable to tell the difference between stool and gas? 7. Have you had a problem causing you to have stools that are liquid? 1=yes 2=no q08 8. Have you found that once you feel the urge to have a bowel movement, you must do so within 15 minutes to avoid an accident? 9. Have you had cramping with a bowel movement? 10. Have you had blood in your bowel movement?" (NCT01198145)
Timeframe: Up to 6 weeks post radiation therapy
| Intervention | percentage of participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| During RT : Q2 | During RT : Q3 | During RT : Q4 | During RT : Q5 | During RT : Q6 | During RT : Q7 | During RT : Q8 | During RT : Q9 | During RT : Q10 | After RT : Q2 | After RT : Q3 | After RT : Q4 | After RT : Q5 | After RT : Q6 | After RT : Q7 | After RT : Q8 | After RT : Q9 | After RT : Q10 | |
| Arm I: Sulfasalazine | 19 | 11 | 33 | 7 | 26 | 11 | 44 | 4 | 7 | 39 | 24 | 55 | 18 | 37 | 37 | 70 | 34 | 50 |
| Arm II: Placebo | 10 | 10 | 33 | 0 | 23 | 20 | 43 | 17 | 7 | 27 | 22 | 56 | 12 | 46 | 37 | 61 | 34 | 29 |
For each patient, an Area Under the Curve (AUC) summary statistic will be calculated taking into account the individual severity of diarrhea toxicity over time. Severity of diarrhea was graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening. The curve was constructed using weekly assessments during and after RT. A separate analysis was done during the course of RT and every week for 6 weeks following RT. (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | grade*week (Mean) | |
|---|---|---|
| During RT | After RT | |
| Arm I: Sulfasalazine | 4.0 | 1.2 |
| Arm II: Placebo | 3.3 | 1.3 |
Tenesmus, Abdominal pain, constipation, diarrhea and hemorrhaging were assessed during RT and up to 6 weeks after RT. Severity of these events were graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening. For each patient, an average score for each outcome variable during and after RT calculated as follows: The sum of all severity scores for that variable divided by the number of severity scores for that variable recorded for the patient during the course of RT and for 6 weeks following RT. (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | Average Grade of Event (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tenesmus during RT | Tenesmus after RT | Abdominal pain during RT | Abdominal pain after RT | Constipation during RT | Constipation after RT | Diarrhea during RT | Diarrhea after RT | Rectal bleeding during RT | Rectal bleeding after RT | |
| Arm I: Sulfasalazine | 0.2 | 0.1 | 0.3 | 0.2 | 0.2 | 0.1 | 0.8 | 0.3 | 0.2 | 0.1 |
| Arm II: Placebo | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.6 | 0.3 | 0.2 | 0.1 |
"The primary endpoint for this study is the maximal severity of diarrhea toxicity. Severity of diarrhea was graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening as measured by the CTCAE version 4.0. Assessments were recorded during the course of RT and for 6 weeks following RT. The table below represents the worst graded diarrhea for each patient.~A two-sided Wilcoxon rank-sum test will be used to test the equality of the distributions of maximum diarrhea severity grades between the two treatment arms." (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Arm I: Sulfasalazine | 10 | 13 | 8 | 10 | 1 |
| Arm II: Placebo | 10 | 15 | 13 | 4 | 0 |
For each arm, the percentage of patients experience clinically significant deficits in overall QOL and fatigue as indicated by a score of 5 or lower on the 0-10 scale. The analysis was done using the questionnaire that was completed during the first week of radiotherapy (RT) and 6 weeks after RT. (NCT01198145)
Timeframe: Up to 6 weeks post radiotherapy
| Intervention | percentage of participants (Number) | |
|---|---|---|
| During RT | After RT | |
| Arm I: Sulfasalazine | 17.9 | 26.9 |
| Arm II: Placebo | 7.5 | 27.6 |
The number of patients that reported any grade 1 or higher adverse event was divided by the total number of patients evaluated. The analysis was done separately for each of the 5 outcomes and separately during RT and after RT. (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tenesmus during RT | Tenesmus after RT | Abdominal pain during RT | Abdominal pain after RT | Constipation during RT | Constipation after RT | Diarrhea during RT | Diarrhea after RT | Rectal bleeding during RT | Rectal bleeding after RT | |
| Arm I: Sulfasalazine | 35.7 | 11.9 | 47.6 | 19.1 | 38.1 | 14.3 | 76.2 | 33.3 | 38.1 | 11.9 |
| Arm II: Placebo | 28.6 | 19.1 | 38.1 | 11.9 | 35.7 | 16.7 | 73.8 | 35.7 | 47.6 | 4.8 |
"The maximal severity of each of 5 different adverse even types (Tenesmus, Abdominal Pain, Constipation, Diarrhea, and Rectal Bleeding) were collected as a secondary endpoint. Severity of the events was graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria (CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening. Adverse events were assessed during the course of RT and for 6 weeks following RT. The table below represents the worst grade for each patient for each type.~Two-sided chi-square tests will be used to compare each percentage variable between treatment arms for each event type." (NCT01198145)
Timeframe: During radiation therapy and up to 6 weeks post radiation therapy
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tenesmus during RT72333267 | Tenesmus during RT72333269 | Tenesmus after RT72333267 | Tenesmus after RT72333269 | Abdominal pain during RT72333267 | Abdominal pain during RT72333269 | Abdominal pain after RT72333269 | Abdominal pain after RT72333267 | Constipation during RT72333267 | Constipation during RT72333269 | Constipation after RT72333269 | Constipation after RT72333267 | Diarrhea during RT72333267 | Diarrhea during RT72333269 | Diarrhea after RT72333269 | Diarrhea after RT72333267 | Rectal bleeding during RT72333267 | Rectal bleeding during RT72333269 | Rectal bleeding after RT72333267 | Rectal bleeding after RT72333269 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Grade 0 | Grade 1 | Grade 4 | Grade 2 | Grade 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm I: Sulfasalazine | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Arm II: Placebo | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 reviews available for sulfasalazine and Diarrhea
| Article | Year |
|---|---|
Medical prevention and treatment of acute and chronic radiation induced enteritis--is there any proven therapy? a short review.
Topics: Abdominal Neoplasms; Acute Disease; Chronic Disease; Combined Modality Therapy; Controlled Clinical | 2008 |
Drug treatment of allergic gastroenteritis.
Topics: Adult; Allergens; Antibody-Producing Cells; Antidiarrheals; Antigen-Antibody Reactions; Aspirin; Dia | 1980 |
[Dietary and drug therapy of intestinal disease].
Topics: Aerophagy; Anti-Inflammatory Agents; Atropine; beta-Galactosidase; Cathartics; Colitis, Ulcerative; | 1980 |
[Ulcerative rectocolitis: current clinical and therapeutic concepts].
Topics: Adrenal Cortex Hormones; Colectomy; Colitis, Ulcerative; Colonic Neoplasms; Colposcopy; Crohn Diseas | 1982 |
[Pathogenesis of chronic inflammatory bowel diseases].
Topics: Adrenal Cortex Hormones; Adult; Cell Membrane Permeability; Child; Colitis, Ulcerative; Crohn Diseas | 1983 |
Collagenous and lymphocytic colitis: subject review and therapeutic alternatives.
Topics: Algorithms; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis; | 1995 |
Collagenous colitis: a cause of chronic diarrhea.
Topics: Age Factors; Barium Sulfate; Biopsy; Chronic Disease; Colitis; Collagen Diseases; Diagnosis, Differe | 1993 |
Massive secretory diarrhea and pseudo-obstruction as the initial presentation of Crohn's disease.
Topics: Anti-Inflammatory Agents; Crohn Disease; Diarrhea; Humans; Intestinal Pseudo-Obstruction; Male; Metr | 1996 |
[Lymphocytic colitis: hypopotassemia as a complication and an association with toxic multinodular goiter].
Topics: Acute Disease; Chronic Disease; Colitis; Diagnosis, Differential; Diarrhea; Female; Gastrointestinal | 2000 |
[Drug-induced enterocolitis. Important differential diagnosis in the investigation of diarrhea and intestinal hemorrhage].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antirheumatic | 2000 |
Basedow's disease and chronic ulcerative colitis: a case report and review of the Japanese literature.
Topics: Adult; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antithyroid Agent | 2001 |
Prostaglandins as factors in diseases of the alimentary tract.
Topics: Aminosalicylic Acids; Bacterial Toxins; Carcinoma; Colonic Neoplasms; Diarrhea; Gallbladder Diseases | 1976 |
Outpatient management of inflammatory bowel disease. Let's keep it as simple as possible.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Ambulatory Care; Aminosalicylic Acids; Anus Diseases; Diarr | 1992 |
Drugs and the ageing gut, liver and pancreas.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Animals; Antacids; Anti-Ulcer Agen | 1985 |
Role of eicosanoids in diarrheal diseases.
Topics: Adrenal Cortex Hormones; Arachidonic Acid; Arachidonic Acids; Bacterial Toxins; Cathartics; Cyclooxy | 1988 |
Chronic diarrhea in childhood: a new look at an old problem.
Topics: Celiac Disease; Chlorides; Chronic Disease; Cystic Fibrosis; Diarrhea; Diet Therapy; Food Hypersensi | 1974 |
8 trials available for sulfasalazine and Diarrhea
| Article | Year |
|---|---|
N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Diarrhea; Double-Blind Method; Enteritis; Female; Hum | 2016 |
Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Diarrhea; Double-Blind Method; F | 1995 |
Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Diarrhea; Double-Blind Method; Female; Finland; Fo | 1995 |
Response to treatment of microscopic colitis.
Topics: Aminosalicylic Acids; Colitis; Colon; Diarrhea; Drug Therapy, Combination; Eosinophils; Female; Foll | 1994 |
Effects of Boswellia serrata gum resin in patients with ulcerative colitis.
Topics: Abdominal Pain; Adolescent; Adult; Biopsy; Blood Proteins; Body Weight; Calcium; Child; Colitis, Ulc | 1997 |
Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy.
Topics: Acute Disease; Administration, Oral; Aged; Chi-Square Distribution; Diarrhea; Double-Blind Method; F | 2000 |
Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
Topics: Adult; Aged; Aminosalicylic Acids; Delayed-Action Preparations; Diarrhea; Drug Carriers; Feces; Fema | 1992 |
Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Chemical Phenomena; Chemistry; Child; Colitis, Ulcera | 1986 |
53 other studies available for sulfasalazine and Diarrhea
| Article | Year |
|---|---|
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis.
Topics: Abdominal Pain; Administration, Oral; Adult; Colitis, Ulcerative; Diarrhea; Disease Progression; Fem | 2021 |
A rare cause of oligoarthritis with septic presentation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Reactive; Diarrhea; Dysuria; Fever; Gastr | 2018 |
Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.
Topics: Abdominal Pain; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Di | 2014 |
Intestinal anti-inflammatory activity of coumarin and 4-hydroxycoumarin in the trinitrobenzenesulphonic acid model of rat colitis.
Topics: 4-Hydroxycoumarins; Acute Disease; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents; Chronic | 2008 |
[A cat with diarrhoea associated with the massive presence of Cyniclomyces guttulatus in the faeces].
Topics: Animals; Antifungal Agents; Cat Diseases; Cats; Diarrhea; Feces; Female; Mycoses; Nystatin; Saccharo | 2009 |
An unusual cause of diarrhoea and arthritis.
Topics: Adult; Anti-Bacterial Agents; Arthritis; Biopsy; Ceftriaxone; Diagnosis, Differential; Diarrhea; Dos | 2013 |
Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cell Proliferation; Colitis; Colon; D | 2010 |
Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model.
Topics: Animals; Antibodies, Monoclonal; Crohn Disease; Diarrhea; Disease Models, Animal; Female; Fingolimod | 2011 |
Diarrhea associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Gastroin | 2003 |
Experience with the use of salazosulfapyridine for intractable diarrhea after hematopoietic stem cell transplantation.
Topics: Adolescent; Diarrhea; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immuno | 2004 |
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, | 2005 |
[Crohn's disease presenting with recurrent acute polyradiculoneuropathy].
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Combined Modality Therapy; Crohn Disease; Diarrhea; Dru | 2007 |
Collagenous colitis in a patient with systemic sclerosis: a rare entity.
Topics: Abdomen; Aged; Autoimmune Diseases; Colitis, Collagenous; Comorbidity; Diarrhea; Female; Humans; Lop | 2007 |
[Clinical features of inflammatory bowel disease (author's transl)].
Topics: Azathioprine; Bacterial Infections; Crohn Disease; Diarrhea; Drug Combinations; Fluid Therapy; Gluco | 1982 |
Diagnosis and medical management of Crohn's disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Crohn Disease; Diagnosis, Differential; Diarrhea; Fo | 1982 |
Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease.
Topics: Colitis, Ulcerative; Crohn Disease; Diarrhea; Drug Tolerance; Dyspepsia; Exanthema; Fever; Humans; R | 1982 |
Microscopic colitis-a cause of chronic watery diarrhoea.
Topics: Adult; Chronic Disease; Colitis; Colon; Diarrhea; Female; Humans; Indomethacin; Male; Middle Aged; P | 1982 |
Nine years of diarrhea and abdominal pain.
Topics: Aged; Crohn Disease; Diarrhea; Duodenal Diseases; Female; Humans; Joint Diseases; Pain; Prednisone; | 1983 |
Clostridium difficile and inflammatory bowel disease.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridium; Colitis, Ulcerative; Crohn Disease; Diarrhea; | 1983 |
Sulphasalazine induced agranulocytosis.
Topics: Acetylation; Adult; Agranulocytosis; Diarrhea; Humans; Male; Middle Aged; Phenotype; Sulfasalazine | 1983 |
Infectious mononucleosis-like manifestations. An adverse reaction to sulfasalazine.
Topics: Adult; Diagnosis, Differential; Diarrhea; Humans; Infectious Mononucleosis; Male; Sulfasalazine; T-L | 1984 |
[An unusual cause of chronic diarrhea: lymphocytic colitis].
Topics: Aged; Chronic Disease; Colitis; Colon; Diarrhea; Drug Combinations; Female; Glucosamine; Humans; Int | 1994 |
Antibodies to human recombinant lipocortin-I in inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Annexin A1; Antibody Specificity; Autoantibodies; Bacterial Infectio | 1993 |
[Diarrhea].
Topics: Colitis; Collagen; Diagnosis, Differential; Diarrhea; Humans; Male; Middle Aged; Sulfasalazine | 1993 |
Collagenous colitis: histopathology and clinical course.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antidiarrheals; Colitis; Collagen; Diarrhe | 1997 |
Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anticholesteremic Agents; Anti | 1996 |
[Acute severe hypersensitivity reaction to salazopirin].
Topics: Adult; Conjunctival Diseases; Diarrhea; Drug Eruptions; Female; Gastrointestinal Agents; Humans; Jau | 1997 |
Sulphasalazine in the treatment of children with chronic arthritis.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Clinical Trials as T | 1998 |
Collagenous colitis in a patient with Addison's disease: a case report.
Topics: Addison Disease; Adult; Colitis; Collagen; Colonoscopy; Diarrhea; Female; Gastrointestinal Agents; H | 1998 |
Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis.
Topics: Animals; Cellulose; Colitis; Diarrhea; Dietary Fiber; Disease Models, Animal; Fatty Acids, Volatile; | 2001 |
Mesalamine intolerance mimics symptoms of active inflammatory bowel disease.
Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Humans; Infla | 2002 |
[Salicylazosulphapyridine for malabsorption in agammoglobulinemia].
Topics: Agammaglobulinemia; Diarrhea; Humans; Malabsorption Syndromes; Sulfasalazine | 1976 |
Diseases of the alimentary system. Acute diarrhoea in adults.
Topics: Adult; Colitis, Ulcerative; Dehydration; Diarrhea; Diphenoxylate; Dysentery, Amebic; Humans; Infusio | 1976 |
Bloody diarrhea--a new complication of sulfasalazine.
Topics: Adolescent; Child; Colitis, Ulcerative; Diarrhea; Female; Gastrointestinal Hemorrhage; Humans; Sulfa | 1978 |
[Transient myopia with angle closure glaucoma. Case report and biometric findings (author's transl)].
Topics: Adult; Diarrhea; Drug Therapy, Combination; Fluocortolone; Glaucoma; Humans; Male; Myopia; Pregnadie | 1978 |
[Crohn's disease: course and prognosis in 169 patients (author's transl)].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Body Weight; Child; Child, Preschool; | 1978 |
Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
Topics: Aminosalicylic Acids; Colitis; Diarrhea; Feces; Humans; Intestinal Mucosa; Male; Sulfapyridine; Sulf | 1979 |
Medical management of inflammatory bowel disease in a spider monkey.
Topics: Animals; Cebidae; Diarrhea; Electrolytes; Female; Inflammatory Bowel Diseases; Monkey Diseases; Pred | 1992 |
Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
Topics: Adolescent; Aminosalicylic Acids; Child; Chronic Disease; Desensitization, Immunologic; Diarrhea; Do | 1992 |
Collagenous colitis as a cause of chronic diarrhea.
Topics: Aged; Chronic Disease; Colitis; Collagen; Diarrhea; Female; Humans; Prednisone; Sulfasalazine | 1990 |
Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway.
Topics: Aminosalicylic Acids; Arachidonic Acid; Arachidonic Acids; Biological Transport; Bradykinin; Colitis | 1985 |
Clostridium difficile toxin in chronic idiopathic colitis.
Topics: Adult; Bacterial Proteins; Bacterial Toxins; Chronic Disease; Clostridium; Clostridium Infections; C | 1986 |
Collagenous colitis and pulmonary fibrosis. Manifestations of a single disease?
Topics: Aged; Colitis; Collagen Diseases; Diarrhea; Dyspnea; Humans; Intestinal Mucosa; Male; Pulmonary Fibr | 1986 |
The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical gastrointestinal effects.
Topics: Animals; Colitis, Ulcerative; Diarrhea; Gastric Mucosa; Gastrointestinal Diseases; Homeostasis; Huma | 1987 |
On the aetiology of ulcerative colitis. A vascular hypothesis.
Topics: Adult; Age Factors; Animals; Child; Colitis, Ulcerative; Diarrhea; Dogs; Female; Gastrointestinal Mo | 1973 |
Colonic complications after renal transplantation.
Topics: Adolescent; Adult; Azathioprine; Cadaver; Colectomy; Colitis; Colon; Diarrhea; Female; Gastrointesti | 1973 |
The drug therapy of ulcerative colitis and of Crohn's disease.
Topics: Adrenocorticotropic Hormone; Atropine; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diarrhea; D | 1974 |
[Hemolysis, formation of Heinz bodies and of methemoglobin under therapy with Azulfidine (author's transl)].
Topics: Adult; Colitis, Ulcerative; Cyanosis; Diarrhea; Erythrocytes; Female; Headache; Heinz Bodies; Hemato | 1974 |
Lincomycin and clindamycin colitis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Clindamycin; Colitis; Diarrhea; Enema; Humans; Inject | 1974 |
Necrotizing vasculitis and ulcerative colitis.
Topics: Adult; Ampicillin; Arthritis; Colitis, Ulcerative; Coumarins; Diarrhea; Edema; Elbow; Heparin; Human | 1974 |
[Ganglioneuroblastoma and ulcerative colitis. Chance association].
Topics: Abdominal Neoplasms; Antineoplastic Agents; Bismuth; Charcoal; Child, Preschool; Colitis, Ulcerative | 1974 |
Electrical potentials of the sigmoid colon and rectum in irritable bowel syndrome and ulcerative colitis.
Topics: Acute Disease; Biological Transport, Active; Colitis, Ulcerative; Colon, Sigmoid; Colonic Diseases, | 1970 |
[Therapy of radiogenic colitis with salicylazosulfapyridine (azulfidine)].
Topics: Cobalt Isotopes; Colitis; Diarrhea; Female; Humans; Radiation Injuries; Radioisotope Teletherapy; Su | 1972 |